MX346185B - Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. - Google Patents
Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.Info
- Publication number
- MX346185B MX346185B MX2013005442A MX2013005442A MX346185B MX 346185 B MX346185 B MX 346185B MX 2013005442 A MX2013005442 A MX 2013005442A MX 2013005442 A MX2013005442 A MX 2013005442A MX 346185 B MX346185 B MX 346185B
- Authority
- MX
- Mexico
- Prior art keywords
- cognitive impairment
- compositions
- methods
- pyridazine derivatives
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41397110P | 2010-11-15 | 2010-11-15 | |
| PCT/US2011/060854 WO2012068161A1 (en) | 2010-11-15 | 2011-11-15 | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013005442A MX2013005442A (es) | 2013-10-03 |
| MX346185B true MX346185B (es) | 2017-03-10 |
Family
ID=46084380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003111A MX383953B (es) | 2010-11-15 | 2011-11-15 | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
| MX2013005442A MX346185B (es) | 2010-11-15 | 2011-11-15 | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003111A MX383953B (es) | 2010-11-15 | 2011-11-15 | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9145372B2 (OSRAM) |
| EP (2) | EP2640391B1 (OSRAM) |
| JP (1) | JP5916746B2 (OSRAM) |
| CN (1) | CN103313712B (OSRAM) |
| AU (1) | AU2011328993B2 (OSRAM) |
| BR (1) | BR112013012062B1 (OSRAM) |
| CA (1) | CA2818025A1 (OSRAM) |
| DK (2) | DK3034079T3 (OSRAM) |
| EA (1) | EA027840B1 (OSRAM) |
| MX (2) | MX383953B (OSRAM) |
| NO (1) | NO3034079T3 (OSRAM) |
| WO (1) | WO2012068161A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383953B (es) | 2010-11-15 | 2025-03-14 | Agenebio Inc | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
| US9612306B2 (en) * | 2010-11-26 | 2017-04-04 | Brigham And Women's Hospital, Inc. | Method for assessing repetitive head injuries with two-dimensional magnetic resonance spectroscopy |
| WO2014047413A1 (en) | 2012-09-21 | 2014-03-27 | Uwm Research Foundation, Inc. | Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma |
| WO2014078377A1 (en) * | 2012-11-14 | 2014-05-22 | Agenebio, Inc. | Methods and compositions for treating schizophrenia |
| MX381561B (es) | 2013-12-20 | 2025-03-12 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo. |
| US10815242B2 (en) | 2015-06-19 | 2020-10-27 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| TWI697485B (zh) * | 2015-07-21 | 2020-07-01 | 日商捷恩智股份有限公司 | 含唑啉環的化合物、含有其的電子輸送/注入層用材料、使用其的有機電致發光元件、顯示裝置及照明裝置 |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CA3104478A1 (en) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11862337B2 (en) | 2019-03-19 | 2024-01-02 | Cambridge Cognition Limited | Method and uses of diagnosing and recommending treatment for a psychotic disorder |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| CA974518A (en) | 1972-04-20 | 1975-09-16 | Merz And Co. | Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds |
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DE10299048I2 (de) | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
| ES2076253T3 (es) | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| DE69131268T2 (de) | 1990-09-21 | 1999-12-30 | Rohm And Haas Co., Philadelphia | Dihydropyridazinone und Pyridazinone als Fungizide |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO1992020682A1 (en) | 1991-05-24 | 1992-11-26 | E.I. Du Pont De Nemours And Company | Arthropodicidal anilides |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (OSRAM) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5763476A (en) | 1994-03-02 | 1998-06-09 | Akzo Noble N.V. | Sublingual or buccal pharmaceutical composition |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| WO1999025353A1 (en) | 1997-11-13 | 1999-05-27 | Merck Sharp & Dohme Limited | Therapeutic uses of triazolo-pyridazine derivatives |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| EP1129094A2 (en) | 1998-11-12 | 2001-09-05 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| WO2000051985A1 (en) | 1999-03-03 | 2000-09-08 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
| GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| PL364081A1 (en) | 2001-03-01 | 2004-12-13 | Pfizer Products Inc. | Use of gaba[a] inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| AU2002313737A1 (en) | 2001-08-13 | 2003-04-01 | University Of Kentucky Research Foundation | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
| EP1471909A4 (en) | 2002-01-16 | 2007-07-25 | Endo Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| GB0218876D0 (en) | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003246979B8 (en) * | 2002-08-13 | 2009-08-06 | Merck Sharp & Dohme Limited | Phenylpyridazine derivatives as ligands for GABA receptors |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| AU2003274353B2 (en) | 2002-10-24 | 2007-04-05 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| CN101249091A (zh) | 2002-11-22 | 2008-08-27 | 约翰斯·霍普金斯大学 | 治疗认知功能障碍的靶位 |
| WO2005079779A1 (en) | 2003-10-22 | 2005-09-01 | Merz Pharma Gmbh & Co. Kgaa | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES |
| KR20070046185A (ko) | 2004-09-23 | 2007-05-02 | 메르츠 파마 게엠베하 운트 코. 카가아 | 소아 행동장애의 치료를 위한 메만틴 |
| MX2007004250A (es) | 2004-10-12 | 2007-06-12 | Hoffmann La Roche | Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos. |
| RU2007112940A (ru) | 2004-10-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные имидазобензодиазепина |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| EP1888594A2 (en) | 2005-05-16 | 2008-02-20 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| EP1924712B1 (en) | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| EP2318005B1 (en) | 2008-08-01 | 2017-11-01 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| BRPI0912587A2 (pt) * | 2008-09-24 | 2015-07-28 | Du Pont | "composto, composição fungicida e método para o controle de doenças vegetais causadas por patógenos fúngicos de plantas" |
| CA2737452C (en) | 2008-09-25 | 2018-05-22 | Vive Nano Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
| WO2010120370A2 (en) | 2009-04-17 | 2010-10-21 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as gabab receptor ligands |
| CA2786716A1 (en) | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| MX383953B (es) | 2010-11-15 | 2025-03-14 | Agenebio Inc | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
| CN103327980A (zh) | 2010-11-15 | 2013-09-25 | 艾吉因生物股份有限公司 | 用于治疗认知障碍的苯并二吖庚因衍生物、组合物和方法 |
| JPWO2012161133A1 (ja) * | 2011-05-20 | 2014-07-31 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
| AU2013312240A1 (en) | 2012-09-10 | 2015-03-19 | Ophirex Inc. | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| MX381561B (es) | 2013-12-20 | 2025-03-12 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo. |
-
2011
- 2011-11-15 MX MX2017003111A patent/MX383953B/es unknown
- 2011-11-15 NO NO15187794A patent/NO3034079T3/no unknown
- 2011-11-15 DK DK15187794.1T patent/DK3034079T3/en active
- 2011-11-15 AU AU2011328993A patent/AU2011328993B2/en not_active Ceased
- 2011-11-15 JP JP2013539003A patent/JP5916746B2/ja active Active
- 2011-11-15 DK DK11841746.8T patent/DK2640391T3/da active
- 2011-11-15 US US13/885,569 patent/US9145372B2/en not_active Expired - Fee Related
- 2011-11-15 EP EP11841746.8A patent/EP2640391B1/en active Active
- 2011-11-15 MX MX2013005442A patent/MX346185B/es active IP Right Grant
- 2011-11-15 WO PCT/US2011/060854 patent/WO2012068161A1/en not_active Ceased
- 2011-11-15 BR BR112013012062-2A patent/BR112013012062B1/pt not_active IP Right Cessation
- 2011-11-15 CA CA2818025A patent/CA2818025A1/en not_active Abandoned
- 2011-11-15 EP EP15187794.1A patent/EP3034079B1/en active Active
- 2011-11-15 EA EA201390712A patent/EA027840B1/ru not_active IP Right Cessation
- 2011-11-15 CN CN201180063261.2A patent/CN103313712B/zh not_active Expired - Fee Related
-
2015
- 2015-09-18 US US14/858,959 patent/US9801879B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX383953B (es) | 2025-03-14 |
| DK2640391T3 (da) | 2016-02-15 |
| CN103313712B (zh) | 2016-10-26 |
| US20130237545A1 (en) | 2013-09-12 |
| NO3034079T3 (OSRAM) | 2018-06-09 |
| JP5916746B2 (ja) | 2016-05-11 |
| CN103313712A (zh) | 2013-09-18 |
| US9801879B2 (en) | 2017-10-31 |
| JP2013542267A (ja) | 2013-11-21 |
| US20160008357A1 (en) | 2016-01-14 |
| MX2013005442A (es) | 2013-10-03 |
| EP2640391A1 (en) | 2013-09-25 |
| DK3034079T3 (en) | 2018-02-05 |
| EP2640391B1 (en) | 2015-11-11 |
| AU2011328993A1 (en) | 2013-06-06 |
| AU2011328993B2 (en) | 2017-03-02 |
| BR112013012062B1 (pt) | 2020-06-02 |
| EA201390712A1 (ru) | 2013-11-29 |
| BR112013012062A2 (pt) | 2016-08-16 |
| US9145372B2 (en) | 2015-09-29 |
| EP3034079A1 (en) | 2016-06-22 |
| EP3034079B1 (en) | 2018-01-10 |
| EA027840B1 (ru) | 2017-09-29 |
| WO2012068161A1 (en) | 2012-05-24 |
| EP2640391A4 (en) | 2014-05-07 |
| CA2818025A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX346185B (es) | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. | |
| EA201390710A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
| MX2016007808A (es) | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo. | |
| CO2018009889A2 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| BR112013033417A2 (pt) | compostos terapêuticos e métodos relacionados de uso | |
| DOP2014000230A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| UY35628A (es) | ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?. | |
| BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
| CL2010000129A1 (es) | Compuestos derivados de benzazepinas fusionadas sustituidas, moduladores del receptor de acetilcolina; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de trastornos del snc tales como esquizofrenia, demencia, enfermedad del alzheimer, esclerosis multiple, entre otras. | |
| MX2017015752A (es) | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo. | |
| CL2009001212A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras. | |
| CL2008003578A1 (es) | Compuestos derivados de imidazo[1,5-a]-quinoxalina, inhibidores pde10; composicion farmaceutica que los comprende y/o kit; procedimiento de preparacion de estos; y su uso en el tratamiento de enfermedades snc | |
| MX2019007338A (es) | Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo. | |
| EA202190076A1 (ru) | Производные бензодиазепина, композиции и способы лечения когнитивных нарушений | |
| CY1123396T1 (el) | Αγωγες συνδυασμου περιλαμβανοντας ιμιδαζοπυραζινονες για την αγωγη ψυχιατρικων και/ή γνωσιακων διαταραχων | |
| AR061637A1 (es) | Composiciones y metodos de tratamiento de trastornos del snc | |
| CL2021001795A1 (es) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina. (divisional de solicitud 202002820) | |
| MX2019007100A (es) | Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso. | |
| CL2011000865A1 (es) | Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras. | |
| CO2023007617A2 (es) | Prevención y/o tratamiento de enfermedades del snc | |
| CL2012000539A1 (es) | Compuestos derivados de acido 3-(morfolin-4-il)-propionico, moduladores de s1p; composicion farmaceutica; utiles en el tratamiento, alivio o prvencion de enfermedades del sistema nervioso central, tales como trastornos neurodegenerativas, enfermedades de alzheimer, depresion mayor, autismo, entre otras. | |
| EA201892113A1 (ru) | Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов | |
| CL2012000650A1 (es) | Compuestos derivados de dihidro- benzocicloalquiloximetil- oxazolopirimidonas sustituidas, moduladores alosterocos de receptores metabortropicos de glutamato ( mglur); composicion famaceutica que los comprende; y uso para el tratamiento y/o prevencion de enfermedades asociadas del snc, como ansiedad, migraña, dolor, entre otras. | |
| EA201691290A1 (ru) | Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения | |
| CL2009000149A1 (es) | Compuestos heterociclos que incluyen un grupo ciclobutoxi sustituido ligandos del receptor h3 composicion farmaceutica que los comprende utiles para tratar enfermedades del sistema nervioso central, tales como deterioro cognitivo leve, alzheimer, trastornos de la memoria, enfermedad de parkinson, esquizofrenia y demencia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |